



Board Communiqué

The Board has carefully considered the recent correspondence from stakeholders concerning the implications of the *LEO Pharma* decision of the Federal Court of Canada.

In light of the fact that the *LEO Pharma* decision came into effect in the middle of the January – June 2007 reporting period, the Board will not require any change in the manner in which average transaction prices for that period are calculated relative to prior reporting periods. Accordingly, patentees may elect to include or exclude all benefits and reductions in the calculations of average transaction prices for January – June 2007, provided that this is consistent with their calculations in prior periods. The Board will advise patentees shortly of the requirements for subsequent periods.

A priority of the Board is that consumers have access to compassionate programs, and the Board is looking at operational options in this regard that will be consistent with the law.

Released on June 28, 2007

Sylvie Dupont
Secretary of the Patented Medicine Prices Review Board
Toll-free number: 1 877 861-2350
Telephone: (613) 954-8299
E-mail address: sdupont@pmprb-cepmb.gc.ca